Spojené státy - angličtina - NLM (National Library of Medicine)

blenheim pharmacal, inc. - metaxalone (unii: 1nma9j598y) (metaxalone - unii:1nma9j598y) - metaxalone 800 mg - skelaxin (metaxalone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. metaxalone does not directly relax tense skeletal muscles in man. known hypersensitivity to any components of this product. known tendency to drug induced, hemolytic, or other anemias. significantly impaired renal or hepatic function.

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - cyproheptadine hydrochloride (unii: nj82j0f8qc) (cyproheptadine - unii:2yhb6175do) - cyproheptadine 4 mg - perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild, uncomplicated allergic skin manifestations of urticaria and angioedema. amelioration of allergic reactions to blood or plasma cold urticaria dermatographism as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. this drug should not be used in newborn or premature infants. because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. hypersensitivity to cyproheptadine and other drugs of similar chemical structure. monoamine oxidase inhibitor therapy (see drug interactions. ) angle-closure glaucoma stenosing peptic ulcer symptomatic prostatic hypertrophy bladder neck obstruction pyloroduodenal obstruction elderly, debilitated patients

Spojené státy - angličtina - NLM (National Library of Medicine)

contract pharmacy services-pa - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 5 mg - glyburide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients with: - known hypersensitivity or allergy to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus, as sole therapy. the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. this warning is based on the study conducted by the university group diabetes program (ugdp), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. the study involved 823 patients who were randomly assigned to one of four treatment groups (diabetes , 19 (suppl. 2):747- 830, 1970). ugdp reported that patients tr

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - potassium citrate (unii: ee90oni6ff) (potassium cation - unii:295o53k152) - potassium citrate 1080 mg - potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (rta) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones. potassium citrate extended-release tablets are contraindicated in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown, or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). potassium citrate extended-release tablets are contraindicated in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esoph

Spojené státy - angličtina - NLM (National Library of Medicine)

state of florida doh central pharmacy - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - indications and usage: for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see precautions ) due to neuroleptic drugs (e.g., phenothiazines). contraindications: hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age and should be used with caution in older pediatric patients. pediatric use: because of the atropine-like side effects, benztropine mesylate should be used with caution in pediatric patients over three years of age (see contradictions ).

Spojené státy - angličtina - NLM (National Library of Medicine)

state of florida doh central pharmacy - cyproheptadine hydrochloride (unii: nj82j0f8qc) (cyproheptadine - unii:2yhb6175do) - indications and usage perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild, uncomplicated allergic skin manifestations of urticaria and angioedema. amelioration of allergic reactions to blood or plasma cold urticaria dermatographism as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. contraindications newborn or premature infants: this drug should not be used in newborn or premature infants. nursing mothers: because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. other conditions: hypersensitivity to cyproheptadine and other drugs of similar chemical structure. monoamine oxidase inhibitor therapy (see drug interactions. ) angle-closure glaucoma stenosing peptic ulcer symptomatic prostatic hypertrophy bladder

Spojené státy - angličtina - NLM (National Library of Medicine)

rebel distributors corp - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients with: - known hypersensitivity or allergy to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus, as sole therapy. the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. this warning is based on the study conducted by the university group diabetes program (ugdp), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. the study involved 823 patients who were randomly assigned to one of four treatment groups (diabetes , 19 (suppl. 2):747- 830, 1970). ugdp reported that patients tr

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets, usp are contraindicated in patients with: - known hypersensitivity or allergy to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus. the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. this warning is based on the study conducted by the university group diabetes program (ugdp), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. the study involved 823 patients who were randomly assigned to one of four treatment groups. ugdp reported that patients treated for 5 to 8 years with diet plus a fixed dos

Spojené státy - angličtina - NLM (National Library of Medicine)

remedyrepack inc. - metaxalone (unii: 1nma9j598y) (metaxalone - unii:1nma9j598y) - metaxalone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. metaxalone does not directly relax tense skeletal muscles in man. known hypersensitivity to any components of this product. known tendency to drug induced, hemolytic, or other anemias. significantly impaired renal or hepatic function.

Spojené státy - angličtina - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - metaxalone (unii: 1nma9j598y) (metaxalone - unii:1nma9j598y) - metaxalone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. metaxalone does not directly relax tense skeletal muscles in man. known hypersensitivity to any components of this product. known tendency to drug induced, hemolytic, or other anemias. significantly impaired renal or hepatic function.